ReviewESMO gastrointestinal oncology2026
Treatment of anal cancer in older patients and patients with frailty.
Review in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy-a retrospective single-centre experience.Clinical and translational radiation oncology · 2027Article
- Outcomes of elderly patients treated with chemoradiotherapy for anal squamous cell carcinoma: a multicenter study of the German cancer consortium - radiation oncology group (DKTK-ROG).Clinical and translational radiation oncology · 2026Article
- Rewriting the future of anal cancer care: From disparities to data-driven decisions.ESMO gastrointestinal oncology · 2026Article
- An international multi-centre study to develop and validate federated learning-based prognostic models for anal cancer.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and age of patients with anal cancer is increasing. With the changing demographics, there is an increasing need to develop harmonised treatment approaches for patients not fit for standard-of-care chemoradiotherapy (CRT). This paper reviews the literature on the treatment of non-metastatic anal cancer in older or frail patients. We then describe assessment and management of frailty in patients with anal cancer. We present results from an international survey of anal cancer clinicians (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.